연구동향 분석

Articles : MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN?

( Xing Ming Ye ) ( Wen Dong Bai ) ( Hua Yu Zhu ) ( Xiao Zhang ) ( Ying Chen ) ( Lei Wang ) ( An Gang Yang ) ( Jing Zh Ao ) ( Lin Tao Jia ) 2014년

논문상세정보
인용/피인용
' Articles : MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN?' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 생물학
  • breast cancer
  • erbb2/her2
  • metastasis
  • mir-221
  • pten
  • trastuzumabresistance
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
1,302 0

0.0%

' Articles : MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN?' 의 참고문헌

  • miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1
    Galardi, S. J. Biol. Chem 282 : 23716 ~ 23724 - [2007]
  • miR-221 & 222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation
    Garofalo, M. Cancer Cell 16 : 498 ~ 509 - [2009]
  • Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer
    Wu, Z. Prostate 73 : 596 ~ 604 - [2013]
  • The role of c-erbB-2/HER2/neu in breast cancer progression and metastases
    Eccles, S. A. J. Mammary Gland Biol. Neoplasia 6 : 393 ~ 406 [2002]
  • The promyelocytic leukemia zinc finger microRNA-221/222 pathway controls melanoma progression through multiple oncogenic mechanisms
    Felicetti, F. Cancer Res 68 : 2745 ~ 2754 - [2008]
  • Targeted therapy in breast cancer: The HER-2/neu gene and protein
    Ross, J. S Mol. Cell Proteomics 3 : 379 ~ 398 - [2004]
  • Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
    Slamon, D. J. Science 244 : 707 ~ 712 - [1989]
  • Phosphoglucose isomerase/ autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells
    Ahmad, A. Cancer Res 71 : 3400 ~ 3409 - [2011]
  • Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
    Baselga, J. J. Clin. Oncol 14 : 737 ~ 744 - [1996]
  • PTEN loss in the continuum of common cancers, rare syndromes and mouse models
    Hollander, M. C. Nat. Rev. Cancer 11 : 289 ~ 301 - [2011]
  • Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells
    Li, J. Mol. Cell Biochem 357 (1-2) : 31 ~ 38 - [2011]
  • Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer
    Miller, T. W. Breast Cancer Research 13 : 224 ~ - [2011]
  • Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
    Cobleigh, M. A. J. Clin. Oncol 17 : 2639 ~ 2648 - [1999]
  • Molecular prognostic factors for breast cancer metastases and survival
    Esteva, F. J. Sem. Radiat. Oncol 12 : 319 ~ 328 - [2002]
  • MicroRNAs: genomics, biogenesis, mechanism, and function
    Bartel, D. P. Cell 116 : 281 ~ 297 - [2004]
  • MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways
    Rao, X. Oncogene 30 : 1082 ~ 1097 - [2011]
  • MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN
    Zhang, C. Z. BMC Cancer 10 : 367 ~ - [2010]
  • MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radio resistance in non-small cell lung cancer cells by targeting PTEN
    Liu, Z. L. Mol. Cell Biochem 372 : 35 ~ 45 - [2013]
  • Involvement of microRNAs in breast cancer
    Adams, B. D. Semin. Reprod. Med 26 : 522 ~ 536 - [2008]
  • Inhibitory effect of knocking down microRNA-221 and microRNA-222 on glioma cell growth in vitro and in vivo
    Zhang, C. Z. Zhonghua Zhong Liu Za Zhi 31 : 721 ~ 726 [2009]
  • Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
    Slamon, D. J. Science 235 : 177 ~ 182 - [1987]
  • HER2 as a prognostic factor in breast cancer
    Menard, S. Oncology 61 (Suppl 2) : 67 ~ 72 - [2001]
  • HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues
    Owens, M. A. Clin. Breast Cancer 5 : 63 ~ 69 [2004]
  • HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas
    Press, M. F. J. Clin. Oncol 15 : 2894 ~ 2904 - [1997]
  • Decreased expression of BRCA1 in SK-BR-3 cells is the result of aberrant activation of the GABP Beta promoter by an NRF-1-containing complex
    Thompson, C. Mol. Cancer 10 : 62 ~ 79 - [2011]
  • Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma
    Johanna, C. B. Cancer 97 : 2972 ~ 2977 [2003]
  • Activated phosphoinositide 3-Kinase/ AKT signaling confers resistance to trastuzumab but not lapatinib mol
    O'Brien, N. A. Cancer Ther 9 : 1489 ~ 1502 [2010]
  • A population-based study on the first forty-eight breast cancer patients receiving trastuzumab (Herceptin) on a named patient basis in Sweden
    Andersson, J. Acta. Oncol 41 : 276 ~ 281 - [2002]